Table 4.
Correlation of SULF‐2 expression and clinico‐pathological factors
| High SULF‐2 [N = 26] | Low SULF‐2 [N = 23] | P‐value | |
|---|---|---|---|
| N (%) | n (%) | ||
| Age: Mean ± SD | 64.3 ± 12.4 | 64.9 ± 10.4 | 0.417 |
| Gender | |||
| Male | 24 (92.3) | 16 (69.6) | 0.04 |
| Female | 2 (7.7) | 7 (30.4) | |
| Clinical stage | |||
| 1 | 20 (77.0) | 4 (17.4) | <0.001 |
| 2 | 2 (7.7) | 1 (4.3) | |
| 3 | 1 (3.8) | 7 (30.4) | |
| 4 | 3 (11.5) | 11 (47.8) | |
| Pathological tumor stage | |||
| T1 | 22 (84.6) | 6 (26.1) | <0.001 |
| T2 | 2 (7.7) | 1 (4.3) | |
| T3 | 2 (7.7) | 14 (60.9) | |
| T4 | 0 (0) | 2 (8.7) | |
| Histological grade | |||
| G1 | 5 (19.2) | 3 (13.0) | 0.764 |
| G2 | 15 (57.7) | 13 (56.5) | |
| G3 | 6 (23.1) | 7 (30.5) | |
| Venous invasion | |||
| v [−] | 22 (84.6) | 5 (21.7) | <0.001 |
| v [+] | 4 (15.4) | 18 (78.3) | |
| Growth pattern | |||
| Expansive (INFa) | 21 (80.8) | 11 (47.8) | 0.017 |
| Intermediate (INFb) | 5 (19.2) | 12 (52.2) | |